Preclinical studies on this topic also confirm these data. The mechanisms of action of the above drugs are fundamentally complex and therefore will not be examined in detail within the scope of this article. To provide a cure for COVID -19 disease by increasing the therapeutic effect of these drugs and reducing their side effects, Khater et al. have prepared nanoparticle formulations of the drugs Fluoxetine hydrochloride (FH), Atomoxteine, Paroxetine, Nisoxteine, RR and Repoxteine SS . In this work, supported by computational studies, the fluoxetine hydrochloride structure was found to bind with high affinity to the major protease enzyme SARS-COV-2. After the optimization studies, the encapsulation efficiency and loading efficiency were determined to be 65.1 ± 2.7% and 10.3 ± 0.4%, respectively. The activity of the nanoparticles against human lung fibroblast cells (CCD-19Lu) is very promising, suggesting that the LPH particles may be an agent against the disease COVID.